NXTC Q1 2020 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+1549.1% YoY

Gross Profit

$12M52.7% margin

Operating Income

$8M36.7% margin

Net Income

$10M43.5% margin

EPS (Diluted)

$3.98

QoQ Revenue Growth

+1016.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$343M

Total Liabilities

$12M

Stockholders' Equity

$332M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$1M	+1549.1%
Gross Profit	$12M	-$5M	+328.9%
Operating Income	$8M	-$7M	+220.5%
Net Income	$10M	-$6M	+258.1%